Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Adaptive Biotechnologies Corp (ADPT)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $277.0M | $179.0M | $170.3M | $185.3M | $154.3M | $98.4M | $85.1M | $55.7M | $38.4M |
| Research & development | $93.8M | $103.0M | $122.1M | $141.8M | $142.3M | $116.1M | $70.7M | $39.2M | $32.0M |
| Operating income | −$57.1M | −$162.5M | −$227.0M | −$200.2M | −$209.0M | −$152.8M | −$78.4M | −$49.8M | −$44.5M |
| EBITDAderived | −$41.1M | −$145.1M | −$207.4M | −$179.3M | −$195.0M | −$144.3M | −$70.6M | −$43.8M | −$38.7M |
| Net income | −$59.5M | −$159.5M | −$225.3M | −$200.2M | −$207.3M | −$146.2M | −$68.6M | −$46.4M | −$42.8M |
| Basic EPSper diluted share | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | -$1.01 | -$3.67 | -$3.50 |
| Diluted EPSper diluted share | -$0.39 | -$1.08 | -$1.56 | -$1.40 | -$1.48 | -$1.11 | -$1.01 | -$3.67 | -$3.50 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 29, 2026Form 4 · 10b5-1 | BENZENO SHARONChief Commercial Ofc Imm Med | SellCommon Stock | 154.8K | $21.14 | $3.27M | 221.3K |
| Jun 26, 2026Form 4 · 10b5-1 | BENZENO SHARONChief Commercial Ofc Imm Med | SellCommon Stock | 11.0K | $21.00 | $231.7K | 272.8K |
| Jun 25, 2026Form 4 · 10b5-1 | BOBULSKY SUSANChief Commercial Officer, MRD | SellCommon Stock | 5.0K | $20.50 | $102.5K | 406.8K |
| Jun 25, 2026Form 4 · 10b5-1 | GRIFFIN MICHELLE RENEEDirector | SellCommon Stock | 52.1K | $20.18 | $1.05M | 15.6K |
| Jun 16, 2026Form 4 · 10b5-1 | ROBINS HARLAN SChief Scientific Officer | SellCommon Stock | 6.2K | $18.01 | $110.9K | 1.41M |